DNMT1 Antikörper (C-Term)

Produktnummer ABIN356564

Produktdetails anti-DNMT1 Antikörper

Target: DNMT1 (DNA (Cytosine-5)-Methyltransferase 1 (DNMT1))

Bindungsspezifität: C-Term

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser DNMT1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Enzyme Immunoassay (EIA)

Spezifität: This antibody reacts with Dnmt1 (C-term).

Aufreinigung: Protein G Chromatography, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.

Immunogen: This Dnmt1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the C-terminal region of human Dnmt1.

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: ELISA: 1/1,000. Western Blot: 1/100-1/500.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.25 mg/mL

Buffer: PBS containing 0.09 % (W/V) Sodium Azide as preservative.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.

Details zu DNMT1

Target: DNMT1 (DNA (Cytosine-5)-Methyltransferase 1 (DNMT1))

Andere Bezeichnung: DNMT1 (DNMT1 Produkte)

Synonyme: cb1075 antikoerper, cb983 antikoerper, dmnt1 antikoerper, fb05h01 antikoerper, mta antikoerper, wu:fb05h01 antikoerper, ADCADN antikoerper, AIM antikoerper, CXXC9 antikoerper, DNMT antikoerper, HSN1E antikoerper, MCMT antikoerper, DDM2 antikoerper, DECREASED DNA METHYLATION 2 antikoerper, DMT01 antikoerper, DMT1 antikoerper, DNA METHYLTRANSFERASE antikoerper, DNA METHYLTRANSFERASE 01 antikoerper, DNA METHYLTRANSFERASE 1 antikoerper, MET2 antikoerper, METHYLTRANSFERASE 2 antikoerper, METHYLTRANSFERASE I antikoerper, METI antikoerper, methyltransferase 1 antikoerper, Cxxc9 antikoerper, Dnmt antikoerper, Dnmt1o antikoerper, MTase antikoerper, Met-1 antikoerper, Met1 antikoerper, MommeD2 antikoerper, m.MmuI antikoerper, DNA methyltransferase 1 antikoerper, DNA (cytosine-5-)-methyltransferase 1 antikoerper, methyltransferase 1 antikoerper, DNA methyltransferase (cytosine-5) 1 antikoerper, DNMT1 antikoerper, dnmt1 antikoerper, Dnmt1 antikoerper, MET1 antikoerper

Hintergrund: Methylation of DNA at cytosine residues plays an important role in regulation of gene expression, genomic imprinting and is essential for mammalian development. Hypermethylation of CpG islands in tumor suppressor genes or hypomethylation of bulk genomic DNA may be linked with development of cancer. To date, 3 families of mammalian DNA methyltransferase genes have been identified which include Dnmt1, Dnmt2 and Dnmt3. Dnmt1 is constitutively expressed in proliferating cells and inactivation of this gene causes global demethylation of genomic DNA and embryonic lethality. Dnmt2 is expressed at low levels in adult tissues and its inactivation does not affect DNA methylation or maintenance of methylation. The Dnmt3 family members, Dnmt3a and Dnmt3b, are strongly expressed in ES cells but their expression is down regulated in differentiating ES cells and is low in adult somatic tissue. Dnmt1 co-purifies with the retinoblastoma (Rb) tumour suppressor gene product, E2F1, and HDAC1. Dnmt1 also cooperates with Rb to repress transcription from promoters containing E2Fbinding sites suggesting a link between DNA methylation, histone deacetylase and sequence-specific DNA binding activity, as well as a growth-regulatory pathway that is disrupted in nearly all cancer cells.Synonyms: AIM, CXXC-type zinc finger protein 9, CXXC9, DNA (cytosine-5)-methyltransferase 1, DNA methyltransferase HsaI, HsaI, MCMT

Gen-ID: 1786, 9606

UniProt: P26358

Pathways: SARS-CoV-2 Protein Interaktom, Phosphorylierungen bei SARS-CoV-2 Infektion